Literature DB >> 29030372

Dose-Dependent Effects of the Myosin Activator Omecamtiv Mecarbil on Cross-Bridge Behavior and Force Generation in Failing Human Myocardium.

Ranganath Mamidi1, Jiayang Li1, Kenneth S Gresham1, Sujeet Verma1, Chang Yoon Doh1, Amy Li1, Sean Lal1, Cristobal G Dos Remedios1, Julian E Stelzer2.   

Abstract

BACKGROUND: Omecamtiv mecarbil (OM) enhances systolic function in vivo by directly binding the myosin cross-bridges (XBs) in the sarcomere. However, the mechanistic details governing OM-induced modulation of XB behavior in failing human myocardium are unclear. METHODS AND
RESULTS: The effects of OM on steady state and dynamic XB behavior were measured in chemically skinned myocardial preparations isolated from human donor and heart failure (HF) left ventricle. HF myocardium exhibited impaired contractile function as evidenced by reduced maximal force, magnitude of XB recruitment (Pdf), and a slowed rate of XB detachment (krel) at submaximal Ca2+ activations. Ca2+ sensitivity of force generation (pCa50) was higher in HF myocardium when compared with donor myocardium, both prior to and after OM incubations. OM incubation (0.5 and 1.0 μmol/L) enhanced force generation at submaximal Ca2+ activations in a dose-dependent manner. Notably, OM induced a slowing in krel with 1.0 μmol/L OM but not with 0.5 μmol/L OM in HF myocardium. Additionally, OM exerted other differential effects on XB behavior in HF myocardium as evidenced by a greater enhancement in Pdf and slowing in the time course of cooperative XB recruitment (Trec), which collectively prolonged achievement of peak force development (Tpk), compared with donor myocardium.
CONCLUSIONS: Our findings demonstrate that OM augments force generation but also prolongs the time course of XB transitions to force-bearing states in remodeled HF myocardium, which may extend the systolic ejection time in vivo. Optimal OM dosing is critical for eliciting enhanced systolic function without excessive prolongation of systolic ejection time, which may compromise diastolic filling.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  heart failure; myocardium; omecamtiv mecarbil; sacromere; systolic function

Mesh:

Substances:

Year:  2017        PMID: 29030372      PMCID: PMC5685665          DOI: 10.1161/CIRCHEARTFAILURE.117.004257

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  40 in total

1.  Different myofilament nearest-neighbor interactions have distinctive effects on contractile behavior.

Authors:  M V Razumova; A E Bukatina; K B Campbell
Journal:  Biophys J       Date:  2000-06       Impact factor: 4.033

2.  Phosphorylation of troponin I and the inotropic effect of adrenaline in the perfused rabbit heart.

Authors:  R J Solaro; A J Moir; S V Perry
Journal:  Nature       Date:  1976-08-12       Impact factor: 49.962

3.  Effect of Ca2+ on cross-bridge turnover kinetics in skinned single rabbit psoas fibers: implications for regulation of muscle contraction.

Authors:  B Brenner
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

4.  Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study.

Authors:  John R Teerlink; G Michael Felker; John J V McMurray; Piotr Ponikowski; Marco Metra; Gerasimos S Filippatos; Justin A Ezekowitz; Kenneth Dickstein; John G F Cleland; Jae B Kim; Lei Lei; Beat Knusel; Andrew A Wolff; Fady I Malik; Scott M Wasserman
Journal:  J Am Coll Cardiol       Date:  2016-03-29       Impact factor: 24.094

5.  Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.

Authors:  John R Teerlink; Cyril P Clarke; Khalil G Saikali; Jacqueline H Lee; Michael M Chen; Rafael D Escandon; Lyndsey Elliott; Rachel Bee; Mohammad Reza Habibzadeh; Jonathan H Goldman; Nelson B Schiller; Fady I Malik; Andrew A Wolff
Journal:  Lancet       Date:  2011-08-20       Impact factor: 79.321

6.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

Authors:  M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson
Journal:  N Engl J Med       Date:  1982-07-22       Impact factor: 91.245

Review 7.  Pathological ventricular remodeling: mechanisms: part 1 of 2.

Authors:  Jana S Burchfield; Min Xie; Joseph A Hill
Journal:  Circulation       Date:  2013-07-23       Impact factor: 29.690

8.  The contributions of cardiac myosin binding protein C and troponin I phosphorylation to β-adrenergic enhancement of in vivo cardiac function.

Authors:  Kenneth S Gresham; Julian E Stelzer
Journal:  J Physiol       Date:  2016-02-01       Impact factor: 5.182

9.  Length-dependent changes in contractile dynamics are blunted due to cardiac myosin binding protein-C ablation.

Authors:  Ranganath Mamidi; Kenneth S Gresham; Julian E Stelzer
Journal:  Front Physiol       Date:  2014-12-02       Impact factor: 4.566

10.  Cardiac Myosin Binding Protein-C Phosphorylation Modulates Myofilament Length-Dependent Activation.

Authors:  Ranganath Mamidi; Kenneth S Gresham; Sujeet Verma; Julian E Stelzer
Journal:  Front Physiol       Date:  2016-02-15       Impact factor: 4.566

View more
  18 in total

1.  Omecamtiv Mecarbil Slows Myosin Kinetics in Skinned Rat Myocardium at Physiological Temperature.

Authors:  Thinh T Kieu; Peter O Awinda; Bertrand C W Tanner
Journal:  Biophys J       Date:  2019-04-25       Impact factor: 4.033

2.  Prof. Cristobal dos Remedios and the Sydney Heart Bank: enabling translatable heart failure research.

Authors:  Joshua B Holmes; Julian E Stelzer
Journal:  Biophys Rev       Date:  2020-06-22

Review 3.  Strategies for targeting the cardiac sarcomere: avenues for novel drug discovery.

Authors:  Joshua B Holmes; Chang Yoon Doh; Ranganath Mamidi; Jiayang Li; Julian E Stelzer
Journal:  Expert Opin Drug Discov       Date:  2020-02-18       Impact factor: 6.098

4.  Sarcomere-based genetic enhancement of systolic cardiac function in a murine model of dilated cardiomyopathy.

Authors:  Jiayang Li; Kenneth S Gresham; Ranganath Mamidi; Chang Yoon Doh; Xiaoping Wan; Isabelle Deschenes; Julian E Stelzer
Journal:  Int J Cardiol       Date:  2018-09-21       Impact factor: 4.164

Review 5.  Cardiomyopathies and Related Changes in Contractility of Human Heart Muscle.

Authors:  Petr G Vikhorev; Natalia N Vikhoreva
Journal:  Int J Mol Sci       Date:  2018-07-31       Impact factor: 5.923

6.  Protein Quality Control Activation and Microtubule Remodeling in Hypertrophic Cardiomyopathy.

Authors:  Larissa M Dorsch; Maike Schuldt; Cristobal G dos Remedios; Arend F L Schinkel; Peter L de Jong; Michelle Michels; Diederik W D Kuster; Bianca J J M Brundel; Jolanda van der Velden
Journal:  Cells       Date:  2019-07-18       Impact factor: 6.600

7.  Omecamtiv mecarbil lowers the contractile deficit in a mouse model of nebulin-based nemaline myopathy.

Authors:  Johan Lindqvist; Eun-Jeong Lee; Esmat Karimi; Justin Kolb; Henk Granzier
Journal:  PLoS One       Date:  2019-11-13       Impact factor: 3.240

8.  Core functional nodes and sex-specific pathways in human ischaemic and dilated cardiomyopathy.

Authors:  Mengbo Li; Benjamin L Parker; Evangeline Pearson; Benjamin Hunter; Jacob Cao; Yen Chin Koay; Oneka Guneratne; David E James; Jean Yang; Sean Lal; John F O'Sullivan
Journal:  Nat Commun       Date:  2020-06-02       Impact factor: 14.919

9.  Impact of the Myosin Modulator Mavacamten on Force Generation and Cross-Bridge Behavior in a Murine Model of Hypercontractility.

Authors:  Ranganath Mamidi; Jiayang Li; Chang Yoon Doh; Sujeet Verma; Julian E Stelzer
Journal:  J Am Heart Assoc       Date:  2018-09-04       Impact factor: 5.501

10.  AAV9 gene transfer of cMyBPC N-terminal domains ameliorates cardiomyopathy in cMyBPC-deficient mice.

Authors:  Jiayang Li; Ranganath Mamidi; Chang Yoon Doh; Joshua B Holmes; Nikhil Bharambe; Rajesh Ramachandran; Julian E Stelzer
Journal:  JCI Insight       Date:  2020-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.